Drug Trial Radar · NCT05804669
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Oct 12, 2023
Primary completion
Aug 25, 2026
Study completion Sep 8, 2026
Sponsor
- Lead sponsor
- Crinetics Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1b/2a, first-in-disease, open-label, multiple-ascending dose exploratory study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamic biomarker responses associated with CRN04894 (an adrenocorticotropic hormone \[ACTH\] receptor antagonist) in participants with ACTH-dependent Cushing's syndrome (Cushing's disease or Ectopic ACTH Syndrome \[EAS\])
Conditions
- Cushing Syndrome
- Cushing Disease
- Ectopic ACTH Syndrome
Interventions
atumelnantDrug
Atumelnant is an orally active investigational agent which antagonizes the action of ACTH at its receptor administered as oral tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with treatment emergent adverse events (TEAEs)Time frame: Up to Day 15
- Proportion of participants with adrenal insufficiencyTime frame: Up to Day 15
- Proportion of participants with safety findings determined by laboratory testingTime frame: Up to Day 15
- Assessment of the maximum observed plasma concentration of CRN04894Time frame: Up to Day 15
- Assessment of the time to achieve maximum observed plasma concentration of CRN04894Time frame: Up to Day 15
- Assessment of the plasma area under the curve of CRN04894Time frame: Up to Day 15
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Institutes of Health (NIH) - National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Bethesda, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.